Evopoint Biosciences Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO20%
Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Evopoint Biosciences Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| XNW28012 NCT06799637 |
P1/2 | Recruiting | Advanced Solid Tumors; Pancreatic Carcinoma | 350 | 2026-12-31 |
| XNW5004 tablets NCT06702605 |
P2 | Not yet recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 50 | 2027-01 |
| XNW29016 NCT06987500 |
P1/2 | Recruiting | Tumor, Solid | 132 | 2027-02-14 |
| XNW28012 for injection NCT07823049 |
P3 | Recruiting | Pancreatic Cancer | 226 | 2027-05-31 |
| XNW5004 NCT06702995 |
P1/2 | Recruiting | Metastatic Castrate-Resistant Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer) | 307 | 2027-07-13 (+14 mo) |
| XNW5004 tablets NCT07545603 |
P2 | Recruiting | Follicular Lymphoma, Grade 1; Follicular Lymphoma, Grade 2 | 65 | 2027-12-31 |
| XNW34017 NCT07327294 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 150 | 2027-12-31 |
| NCT06776952 NCT06776952 |
P3 | Recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 120 | 2028-01 |
| XNW5004 combined with CHOP (incremental) NCT07730515 |
P1/2 | Recruiting | Non-hodgkin Lymphoma; Peripheral T-cell Lymphoma | 176 | 2028-09-30 |
| XNW5004 Tablet NCT07730580 |
P2 | Not yet recruiting | Advanced Prostate Cancer | 242 | 2028-12-31 |